- Home
- TNGX vs RCKT Comparison
TNGX vs RCKT Comparison
Compare TNGX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- RCKT
- Stock Information
- Founded
- TNGX 2014
- RCKT 1999
- Country
- TNGX United States
- RCKT United States
- Employees
- TNGX N/A
- RCKT N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- TNGX Health Care
- RCKT Health Care
- Exchange
- TNGX Nasdaq
- RCKT Nasdaq
- Market Cap
- TNGX 351.2M
- RCKT 326.4M
- IPO Year
- TNGX N/A
- RCKT N/A
- Fundamental
- Price
- TNGX $5.16
- RCKT $2.70
- Analyst Decision
- TNGX Strong Buy
- RCKT Buy
- Analyst Count
- TNGX 6
- RCKT 13
- Target Price
- TNGX $12.20
- RCKT $18.50
- AVG Volume (30 Days)
- TNGX 3.9M
- RCKT 8.4M
- Earning Date
- TNGX 08-06-2025
- RCKT 08-04-2025
- Dividend Yield
- TNGX N/A
- RCKT N/A
- EPS Growth
- TNGX N/A
- RCKT N/A
- EPS
- TNGX N/A
- RCKT N/A
- Revenue
- TNGX $40,990,000.00
- RCKT N/A
- Revenue This Year
- TNGX N/A
- RCKT N/A
- Revenue Next Year
- TNGX N/A
- RCKT N/A
- P/E Ratio
- TNGX N/A
- RCKT N/A
- Revenue Growth
- TNGX 10.09
- RCKT N/A
- 52 Week Low
- TNGX $1.03
- RCKT $2.19
- 52 Week High
- TNGX $12.02
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- TNGX 79.99
- RCKT 32.09
- Support Level
- TNGX $4.40
- RCKT $2.66
- Resistance Level
- TNGX $5.37
- RCKT $3.33
- Average True Range (ATR)
- TNGX 0.65
- RCKT 0.28
- MACD
- TNGX 0.10
- RCKT 0.09
- Stochastic Oscillator
- TNGX 93.68
- RCKT 26.59
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.